Thanh bên bài viết

PDF
Đã xuất bản: 2024-07-31
Số lượt xem tóm tắt: 66
Số lượt xem PDF: 39
DOI: https://doi.org/10.52852/tcncyh.v179i6.2475
Số xuất bản
Tập 179 Số 6 (2024)
Chuyên mục
Các bài báo
Cách trích dẫn
Mai, C. T. P., Phuong, D. T. M., Ha, N. T. V., & Trang, T. T. H. (2024). 33. Treatment outcomes and CYP3A4*1G genotype distribution in children with peptic ulcers. Tạp Chí Nghiên cứu Y học, 179(6), 311-319. https://doi.org/10.52852/tcncyh.v179i6.2475

33. Treatment outcomes and CYP3A4*1G genotype distribution in children with peptic ulcers

Chu Thi Phuong Mai, Do Thi Minh Phuong, Nguyen Thi Viet Ha, Tran Thi Huyen Trang

Nội dung chính của bài viết

Tóm tắt

Many factors, including the role of the cytochrome P450 system such as CYP3A4*1G, may influence the effectiveness of peptic ulcer treatment. The study aimed to describe the treatment outcomes and distribution of CYP3A4*1G genotype in children with peptic ulcers. A descriptive cross-sectional study, longitudinal follow-up before and after six weeks of treatment was conducted on 100 children with peptic ulcers from October 2022 to February 2024. Children with peptic ulcers without H. pylori infection had a higher rate of anemia, and pyloric and duodenal deformation, compatible with children with H. pylori. The ulcer healing rate was lower in children with deep peptic ulcers, excess eosinophils in mucosal biopsies, and poor therapeutic compliance. The distribution of CYP3A4*1/*1, CYP3A4*1/CYP3A4*1G, CYP3A4*1G/CYP3A4*1G in the study was 43.2%, 48.1%, and 8.6%, respectively, with no difference by gender. There were no difference in ulcer healing rates according to the presence of the CYP3A4*1G variant. In conclusion, the degree of peptic ulcer healing in children varies according to several characteristics. However, there were no difference in ulcer healing rates according to the presence of the CYP3A4*1G variant.

Chi tiết bài viết

Từ khóa

Treatment outcome, peptic ulcer, children, CYP3A4*1G

Tài liệu tham khảo

1. Xie X, Ren K, Zhou Z, et al. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study. BMC Gastroenterology. 2022; 22(1):58. doi:10.1186/s12876-022-02130-2.
2. Guariso G, Gasparetto M. Update on Peptic Ulcers in the Pediatric Age. Ulcers. 2012; 2012:e896509. doi:10.1155/2012/896509.
3. Shu-Ching H, Bor-Shyang S, Shui-Cheng L, et al. East etiology and treatment of childhood peptic ulcer disease in Taiwan: a single center 9-year experience. African Medical Journal. 2009; 86(3): 100-109.
4. Preissner SC, Hoffmann MF, Preissner R, Dunkel M, Gewiess A, Preissner S. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One. 2013; 8(12): e82562. Published 2013 Dec 10. doi:10.1371/journal.pone.0082562.
5. Karaca RO, Kalkisim S, Altinbas A, et al. Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. Basic & Clinical Pharmacology & Toxicology. 2017; 120(2): 199-206. doi:10.1111/bcpt.12667.
6. Fohner AE, Dalton R, Skagen K, et al. Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function. Clin Transl Sci. 2021; 14(4): 1292-1302. doi:10.1111/cts.12970.
7. Sutrisna E, Dwiprahasto I, Kristin E. CYP3A4*1G gene Polymorphism on Javanese People. Indonesian Journal of Biotechnology. 2015; 16:83. doi:10.22146/ijbiotech.16373.
8. Lanas A, Chan FKL. Peptic ulcer disease. Lancet Lond Engl. 2017; 390(10094): 613-624. doi:10.1016/S0140-6736(16)32404-7.
9. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). Journal of Pediatric Gastroenterology and Nutrition. 2017; 64(6): 991-1003. doi:10.1097/MPG.0000000000001594.
10. Komori H, Ueyama H, Nagahara A, et al. A prospective randomized trial of a potassium competitive acid blocker vs proton pump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia. J Int Med Res. 2019; 47(4): 1441-1452. doi:10.1177/0300060519828514.
11. Wermeille J, Cunningham M, Dederding JP, et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause?. Gastroenterol Clin Biol. 2002; 26(3): 216-219.
12. O’Connor JPA, Taneike I, O’Morain C. Improving Compliance with Helicobacter Pylori Eradication Therapy: When and How? Therap Adv Gastroenterol. 2009; 2(5): 273-279. doi:10.1177/1756283X09337342.
13. Broutet N, Tchamgoué S, Pereira E, et al. Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003; 17(1): 99-109. doi:10.1046/j.1365-2036.2003.01396.x.
14. Sapone A, Vaira D, Trespidi S, et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol. 2003; 98(5): 1010-1015. doi:10.1111/j.1572-0241.2003.07427.x.